Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations
- PMID: 7776504
Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations
Abstract
Objective: To summarize consensus recommendations for off-label uses of standard intravenous immunoglobulin (IVIG), as developed by a University Hospital Consortium (UHC) Expert Panel. These findings are intended to help guide clinicians in the appropriate and efficient use of IVIG.
Participants: The UHC-sponsored panel included eight physicians (board certified in critical care, hematology, immunology, neurology, oncology, pediatrics, or rheumatology) and two hospital pharmacists.
Evidence: MEDLINE and EMBASE were searched to identify all English-language review articles (n = 201) and original reports (n = 1904) on IVIG (human use only, excluding editorials, letters, and comments) published between January 1982 and March 1994. Relevant original reports (250) and review articles (87) were evaluated by the first author (T.A.R.). Extracted data included laboratory and clinical findings, objective measures, or clinical impressions. The evidence quality was graded by study design according to the US Preventive Services Task Force.
Consensus process: Before the panel meeting, a draft literature review and recommendations were produced by one of the authors (T.A.R.). The recommendations herein represent consensus (100% agreement) based on the published evidence.
Conclusions: The UHC Expert Panel made specific recommendations for 53 off-label indications and the following general recommendations: (1) Usually IVIG is indicated only if standard approaches have failed, become intolerable, or are contraindicated; (2) IVIG products should be considered therapeutically equivalent and interchangeable; (3) interproduct pharmaceutical differences should be considered with the patient's clinical and physiological status when selecting an IVIG product; and (4) currently, IVIG manufacturers cannot guarantee freedom from viral contamination in the finished product.
Comment in
- ACP J Club. 1996 Jan-Feb;124(1):7
Similar articles
-
A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers.Ann Pharmacother. 2000 Mar;34(3):295-9. doi: 10.1345/aph.19252. Ann Pharmacother. 2000. PMID: 10917372
-
Guidelines on the use of intravenous immune globulin for hematologic conditions.Transfus Med Rev. 2007 Apr;21(2 Suppl 1):S9-56. doi: 10.1016/j.tmrv.2007.01.001. Transfus Med Rev. 2007. PMID: 17397769
-
IGIV in neurology--evidence and recommendations.Can J Neurol Sci. 1999 May;26(2):139-52. Can J Neurol Sci. 1999. PMID: 10352875 Review.
-
Guidelines on the use of intravenous immune globulin for neurologic conditions.Transfus Med Rev. 2007 Apr;21(2 Suppl 1):S57-107. doi: 10.1016/j.tmrv.2007.01.002. Transfus Med Rev. 2007. PMID: 17397768
-
Unlabeled uses of intravenous immune globulin.Am J Health Syst Pharm. 2008 Oct 1;65(19):1815-24. doi: 10.2146/ajhp070582. Am J Health Syst Pharm. 2008. PMID: 18796422 Review.
Cited by
-
Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody.J Neurooncol. 2007 Jan;81(1):67-9. doi: 10.1007/s11060-006-9198-x. Epub 2006 Jun 14. J Neurooncol. 2007. PMID: 16773214
-
Application of systematic review methodology to the field of nutrition.J Nutr. 2008 Dec;138(12):2297-306. doi: 10.3945/jn.108.097154. J Nutr. 2008. PMID: 19022948 Free PMC article.
-
Optimal attenuation of experimental autoimmune encephalomyelitis by intravenous immunoglobulin requires an intact interleukin-11 receptor.PLoS One. 2014 Jul 31;9(7):e101947. doi: 10.1371/journal.pone.0101947. eCollection 2014. PLoS One. 2014. PMID: 25078447 Free PMC article.
-
Intravenous immunoglobulin treatment in neurological diseases.J Neurol Neurosurg Psychiatry. 1996 Apr;60(4):359-61. doi: 10.1136/jnnp.60.4.359. J Neurol Neurosurg Psychiatry. 1996. PMID: 8774395 Free PMC article. Review. No abstract available.
-
Criteria for the appropriate drug utilisation of immunoglobulin.Pharmacoeconomics. 1996 May;9(5):417-29. doi: 10.2165/00019053-199609050-00005. Pharmacoeconomics. 1996. PMID: 10160254 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources